磁共振靶向穿刺与系统穿刺在前列腺癌主动监测中检测分级进展的比较
本研究纳入369例接受主动监测的前列腺癌患者,比较磁共振靶向穿刺与系统穿刺在2年、4年及6年以上检测分级进展的能力。2年时靶向穿刺、系统穿刺和联合穿刺分别检出15.9%、26.4%和32.5%的分级进展,靶向穿刺显著优于系统穿刺(p<0.001),且51.1%的进展仅由靶向穿刺发现。结论支持将前列腺磁共振及靶向穿刺纳入主动监测方案。
要点
- 磁共振靶向穿刺在2年时检测分级进展显著优于系统穿刺(p<0.001)。
- 联合穿刺检出率最高,2年时达32.5%。
- 超过半数(51.1%)进展仅被靶向穿刺发现。
核心结论
- 磁共振靶向穿刺在主动监测队列中2年时检出的分级进展显著多于系统穿刺,应纳入现代主动监测方案。
研究设计与样本
- 回顾性队列研究,纳入2007年7月至2020年1月间369例接受主动监测且至少监测1年的前列腺癌患者。
主要发现
- 2年时系统穿刺、磁共振靶向穿刺和联合穿刺分别检出44例(15.9%)、73例(26.4%)和90例(32.5%)分级进展。
- 磁共振靶向穿刺在低危和中危人群中检出的分级进展均多于系统穿刺(p<0.001)。
- 2年时90例分级进展中46例(51.1%)仅由磁共振靶向穿刺发现而系统穿刺漏诊。
临床怎么用
- 在前列腺癌主动监测中应纳入前列腺磁共振和影像靶向穿刺以更准确检测分级进展。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Active surveillance for patients with low and intermediate risk prostate cancers is becoming a more utilized option in recent years. However, the use of magnetic resonance imaging and imaging-targeted biopsy for monitoring grade progression has been poorly studied in this population. We aim to define the utility of magnetic resonance imaging-targeted biopsy and systematic biopsy in an active surveillance population. MATERIALS AND METHODS: Between July 2007 and January 2020, patients with diagnosed prostate cancer who elected active surveillance were monitored with prostate magnetic resonance imaging, imaging-targeted biopsy and standard systematic biopsy. Patients were eligible for surveillance if diagnosed with any volume Gleason grade 1 disease and select Gleason grade 2 disease. Grade progression (Gleason grade 1 to ≥2 disease and Gleason grade 2 to ≥3 disease) for each biopsy modality was measured at 2 years, 4 years and 6+ years. RESULTS: In total, 369 patients had both magnetic resonance imaging-targeted and systematic biopsy and were surveilled for at least 1 year. At 2 years, systematic biopsy, magnetic resonance imaging-targeted biopsy and combined biopsy (systematic+imaging-targeted) detected grade progression in 44 patients (15.9%), 73 patients (26.4%) and 90 patients (32.5%), respectively. Magnetic resonance imaging-targeted biopsy detected more cancer grade progression compared to systematic biopsy in both the low and intermediate risk populations (p <0.001). Of all 90 grade progressions at the 2-year time point 46 (51.1%) were found by magnetic resonance imaging-targeted biopsy alone and missed by systematic biopsy. CONCLUSIONS: Magnetic resonance imaging-targeted biopsy detected significantly more grade progressions in our active surveillance cohort compared to systematic biopsy at 2 years. Our results provide compelling evidence that prostate magnetic resonance imaging and imaging-targeted biopsy should be included in contemporary active surveillance protocols.
引用
- Yerram NK, Long L, O'Connor LP, et al. Magnetic Resonance Imaging-Targeted and Systematic Biopsy for Detection of Grade Progression in Patients on Active Surveillance for Prostate Cancer. J Urol. 2020. PMID: 33356479. doi:10.1097/JU.0000000000001547
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。